We are live on ! Find out more
ANGO icon

AngioDynamics

138 hedge funds and large institutions have $251M invested in AngioDynamics in 2024 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 59 increasing their positions, 36 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

139% more call options, than puts

Call options by funds: $74K | Put options by funds: $31K

64% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 36

28% more capital invested

Capital invested by funds: $197M → $251M (+$54.4M)

0% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 20

1% less funds holding

Funds holding: 139138 (-1)

1.7% less ownership

Funds ownership: 81.18%79.48% (-1.7%)

Holders
138
Holders Change
-1
Holders Change %
-0.72%
% of All Funds
1.98%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
20
Increased
59
Reduced
36
Closed
20
Calls
$74K
Puts
$31K
Net Calls
+$43K
Net Calls Change
+$24K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$36.3M +$404K +55,916 +1%
SFM
2
Systematic Financial Management
New Jersey
$18.8M +$2.17M +300,785 +14%
Vanguard Group
3
Vanguard Group
Pennsylvania
$17.8M +$725K +100,405 +5%
Millennium Management
4
Millennium Management
New York
$17.4M +$3.19M +441,998 +25%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$10.5M +$1.74M +240,750 +22%
Renaissance Technologies
6
Renaissance Technologies
New York
$8.22M -$295K -40,800 -4%
KLP
7
Kent Lake PR
Puerto Rico
$7.78M +$7.22M +1,000,000 New
RA
8
Royce & Associates
New York
$7.67M +$694K +96,138 +11%
AC
9
Armistice Capital
New York
$7.48M +$910K +126,000 +15%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$7.48M +$335K +46,409 +5%
N
11
Nuveen
North Carolina
$7.34M +$337K +46,665 +5%
SBH
12
Segall Bryant & Hamill
Illinois
$7.09M +$3.87M +535,958 +143%
State Street
13
State Street
Massachusetts
$6.3M +$153K +21,218 +3%
Morgan Stanley
14
Morgan Stanley
New York
$4.76M -$3.42M -473,448 -44%
JP Morgan Chase
15
JP Morgan Chase
New York
$4.3M +$890K +123,271 +29%
Assenagon Asset Management
16
Assenagon Asset Management
Luxembourg
$3.31M +$206K +28,499 +7%
Jacobs Levy Equity Management
17
Jacobs Levy Equity Management
New Jersey
$3.22M -$687K -95,157 -19%
AI
18
Acuitas Investments
Washington
$3.14M
First Eagle Investment Management
19
First Eagle Investment Management
New York
$3.07M +$1.27M +175,745 +80%
Two Sigma Advisers
20
Two Sigma Advisers
New York
$2.97M -$1.35M -186,500 -33%
Two Sigma Investments
21
Two Sigma Investments
New York
$2.74M -$959K -132,873 -27%
Northern Trust
22
Northern Trust
Illinois
$2.67M +$3.71K +514 +0.2%
Charles Schwab
23
Charles Schwab
California
$2.54M +$83.8K +11,599 +4%
RHJA
24
Rice Hall James & Associates
California
$2.39M -$20.8K -2,885 -0.9%
AQR Capital Management
25
AQR Capital Management
Connecticut
$2.37M -$42.3K -5,851 -2%

ANGO Hedge Fund Activity: Q3 2024 in Review

138 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in AngioDynamics (ANGO) for Q3 2024, worth a combined $251M — up 28% from $197M a quarter earlier.

Fund positioning in ANGO was balanced in Q3 2024: 20 funds opened new positions, 20 closed out, 59 added to existing stakes and 36 trimmed.

The largest buyer was Segall Bryant & Hamill, adding an estimated $3.87M. The largest seller was ExodusPoint Capital Management, cutting an estimated $6.89M.

  • 138 institutional investors held AngioDynamics (ANGO) as of Q3 2024, down from 139 in Q2 2024.
  • Funds reported $251M of AngioDynamics stock for Q3 2024, up 28% quarter-over-quarter.
  • 20 funds opened new AngioDynamics positions in Q3 2024 and 20 closed out, a net change of 0 holders.
  • The largest AngioDynamics buyer in Q3 2024 was Segall Bryant & Hamill, an estimated $3.87M added.
  • The largest AngioDynamics seller in Q3 2024 was ExodusPoint Capital Management, an estimated $6.89M sold.

Based on aggregated 13F filings for Q3 2024.